Clinical Trial Update: Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children [Phase 2]

View source ↗

Summary

Phase 2 pilot study of cabozantinib for recurrent or progressive central nervous system tumors in children has been terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• High-grade Glioma
• Malignant Brain Tumor

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Indiana University | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 | Status: TERMINATED | Results posted: 2022-08-15